These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27709663)

  • 1. The MAPT gene is differentially methylated in the progressive supranuclear palsy brain.
    Huin V; Deramecourt V; Caparros-Lefebvre D; Maurage CA; Duyckaerts C; Kovari E; Pasquier F; Buée-Scherrer V; Labreuche J; Behal H; Buée L; Dhaenens CM; Sablonnière B
    Mov Disord; 2016 Dec; 31(12):1883-1890. PubMed ID: 27709663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
    Park HJ; Lee KW; Oh S; Yan R; Zhang J; Beach TG; Adler CH; Voronkov M; Braithwaite SP; Stock JB; Mouradian MM
    J Neuropathol Exp Neurol; 2018 Feb; 77(2):139-148. PubMed ID: 29281045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains.
    Ingelsson M; Ramasamy K; Russ C; Freeman SH; Orne J; Raju S; Matsui T; Growdon JH; Frosch MP; Ghetti B; Brown RH; Irizarry MC; Hyman BT
    Acta Neuropathol; 2007 Nov; 114(5):471-9. PubMed ID: 17721707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.
    Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM
    Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Cope TE; Rittman T; Borchert RJ; Jones PS; Vatansever D; Allinson K; Passamonti L; Vazquez Rodriguez P; Bevan-Jones WR; O'Brien JT; Rowe JB
    Brain; 2018 Feb; 141(2):550-567. PubMed ID: 29293892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau and saitohin gene expression pattern in progressive supranuclear palsy.
    Ezquerra M; Gaig C; Ascaso C; Muñoz E; Tolosa E
    Brain Res; 2007 May; 1145():168-76. PubMed ID: 17320831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
    Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.
    Allen M; Burgess JD; Ballard T; Serie D; Wang X; Younkin CS; Sun Z; Kouri N; Baheti S; Wang C; Carrasquillo MM; Nguyen T; Lincoln S; Malphrus K; Murray M; Golde TE; Price ND; Younkin SG; Schellenberg GD; Asmann Y; Ordog T; Crook J; Dickson D; Ertekin-Taner N
    Acta Neuropathol; 2016 Aug; 132(2):197-211. PubMed ID: 27115769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
    Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
    Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy.
    Zemaitaitis MO; Lee JM; Troncoso JC; Muma NA
    J Neuropathol Exp Neurol; 2000 Nov; 59(11):983-9. PubMed ID: 11089576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration.
    Takanashi M; Mori H; Arima K; Mizuno Y; Hattori N
    Brain Res Mol Brain Res; 2002 Aug; 104(2):210-9. PubMed ID: 12225876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
    Malarte ML; Gillberg PG; Kumar A; Bogdanovic N; Lemoine L; Nordberg A
    Mol Psychiatry; 2023 Mar; 28(3):1272-1283. PubMed ID: 36447011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.
    Ressler HW; Humphrey J; Vialle RA; Babrowicz B; Kandoi S; Raj T; Dickson DW; Ertekin-Taner N; Crary JF; Farrell K
    Acta Neuropathol Commun; 2024 Aug; 12(1):135. PubMed ID: 39154163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau imaging with [
    Ishiki A; Harada R; Okamura N; Tomita N; Rowe CC; Villemagne VL; Yanai K; Kudo Y; Arai H; Furumoto S; Tashiro M; Furukawa K
    Eur J Neurol; 2017 Jan; 24(1):130-136. PubMed ID: 27797445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.
    Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA
    JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration.
    Briel N; Pratsch K; Roeber S; Arzberger T; Herms J
    Brain Pathol; 2021 Jul; 31(4):e12914. PubMed ID: 33089580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.
    Koga S; Kouri N; Walton RL; Ebbert MTW; Josephs KA; Litvan I; Graff-Radford N; Ahlskog JE; Uitti RJ; van Gerpen JA; Boeve BF; Parks A; Ross OA; Dickson DW
    Acta Neuropathol; 2018 Sep; 136(3):389-404. PubMed ID: 29926172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation patterns in the frontal lobe white matter of multiple system atrophy, Parkinson's disease, and progressive supranuclear palsy: a cross-comparative investigation.
    Murthy M; Fodder K; Miki Y; Rambarack N; De Pablo Fernandez E; Pihlstrøm L; Mill J; Warner TT; Lashley T; Bettencourt C
    Acta Neuropathol; 2024 Jul; 148(1):4. PubMed ID: 38995454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.
    Pittman AM; Myers AJ; Abou-Sleiman P; Fung HC; Kaleem M; Marlowe L; Duckworth J; Leung D; Williams D; Kilford L; Thomas N; Morris CM; Dickson D; Wood NW; Hardy J; Lees AJ; de Silva R
    J Med Genet; 2005 Nov; 42(11):837-46. PubMed ID: 15792962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome.
    Tsuboi Y; Josephs KA; Boeve BF; Litvan I; Caselli RJ; Caviness JN; Uitti RJ; Bott AD; Dickson DW
    Mov Disord; 2005 Aug; 20(8):982-8. PubMed ID: 15834857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.